Line 58: | Line 58: | ||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/Human_Practices">Overview</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Human_Practices">Overview</a></li> | ||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/HP/Silver">Societal Issues of CRISPR/Cas9</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/HP/Silver">Societal Issues of CRISPR/Cas9</a></li> | ||
− | |||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/HP/Gold">Responsible Research and Innovation</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/HP/Gold">Responsible Research and Innovation</a></li> | ||
+ | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Human_Practices/GMO_Regulation">GMO regulation</a></li> | ||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/Integrated_Practices">Integrated Practices</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Integrated_Practices">Integrated Practices</a></li> | ||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/Engagement">Engagement</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Engagement">Engagement</a></li> |
Latest revision as of 14:54, 18 October 2016